Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
BioCryst ( (BCRX) ) has provided an announcement.
On May 4, 2026, BioCryst Pharmaceuticals, Inc. announced it had signed a license agreement granting an Irish affiliate of Neopharmed Gentili S.p.A. exclusive rights to commercialize the investigational HAE drug navenibart in Europe. BioCryst will receive $70 million upfront, up to $275 million in potential regulatory and sales milestone payments, and tiered royalties on European net sales ranging from 18% to 30%.
The deal extends the partners’ existing relationship following the 2025 sale of BioCryst’s European ORLADEYO business to Neopharmed Gentili, and aligns with BioCryst’s strategy to focus its own commercial efforts on the U.S. while leveraging Neopharmed’s regional infrastructure. BioCryst’s Phase 3 program for navenibart in hereditary angioedema continues, with development intended to support a U.S. regulatory filing by the end of 2027, and the transaction is expected to strengthen BioCryst’s balance sheet while preserving meaningful upside for shareholders through milestones and royalties.
The most recent analyst rating on (BCRX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.
Spark’s Take on BCRX Stock
According to Spark, TipRanks’ AI Analyst, BCRX is a Outperform.
The score is driven by a sharp 2025 financial turnaround (profitability and free cash flow) and supportive valuation (low P/E), reinforced by constructive 2026 guidance and pipeline progress. The main offsets are balance-sheet structure risk (negative equity) and near-term technical overbought signals that can raise volatility.
To see Spark’s full report on BCRX stock, click here.
More about BioCryst
BioCryst Pharmaceuticals, Inc. is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company has commercialized ORLADEYO (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of oral small-molecule and injectable protein therapeutics for a range of rare conditions.
BioCryst’s market position centers on rare disease therapeutics, particularly in HAE, where it is building a portfolio that combines an established oral therapy with late-stage pipeline assets. By partnering with regional specialists, the company aims to maximize commercial reach while concentrating its own resources on priority markets and pipeline advancement, reinforcing its role as a focused rare-disease innovator.
Average Trading Volume: 5,171,179
Technical Sentiment Signal: Strong Buy
Current Market Cap: $2.34B
Find detailed analytics on BCRX stock on TipRanks’ Stock Analysis page.